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Epigenetics refers to a heritable change in the pattern of
gene expression that is mediated by a mechanism specifically
not due to alterations in the primary nucleotide sequence.
Well-known epigenetic mechanisms encompass DNA
methylation, chromatin remodeling (histone modifications),
and RNA interference. Functionally, epigenetics provides
an extra layer of transcriptional control and plays a crucial
role in normal physiological development, as well as in
pathological conditions. Aberrant DNA methylation is
implicated in immune dysfunction, inflammation, and insulin
resistance. Epigenetic changes may be responsible for
‘metabolic memory’ and development of micro- and
macrovascular complications of diabetes. MicroRNAs are
critical in the maintenance of glomerular homeostasis and
hence RNA interference may be important in the progression
of renal disease. Recent studies have shown that epigenetic
modifications orchestrate the epithelial–mesenchymal
transition and eventually fibrosis of the renal tissue.
Oxidative stress, inflammation, hyperhomocysteinemia,
and uremic toxins could induce epimutations in chronic
kidney disease. Epigenetic alterations are associated with
inflammation and cardiovascular disease in patients with
chronic kidney disease. Reversible nature of the epigenetic
changes gives a unique opportunity to halt or even reverse
the disease process through targeted therapeutic strategies.
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The nucleus has to take care of the inheritance of the
heritable characters, while the surrounding cytoplasm is
concerned with accommodation or adaptation to the
environment.
Ernst Haeckel
The Human Genome Project has revealed thousands of genes
and millions of sequence variations that might influence
human health.1 Completion of the International HapMap
Project and the recent advances in genotyping technologies
has led to a surge in genome-wide association studies.2 These
studies have certainly broadened our understanding of the
genetic basis of many complex traits2,3 often implicating
previously unsuspected biological pathways. However, for
most common traits studied, known gene polymorphisms
explain only a fraction of associated risk, suggesting that
sequence variations in the human genome are only part
of the puzzle leading to the evolution of the nascent field of
epigenetics. The term ‘epigenetics’ was first used by Conrad
Waddington to explain the interactions of genes with their
environment,4 and is increasingly being examined as one of
the important determinants of complex human diseases.5,6
This review provides an overview of recent advances in the
field of epigenetics with specific reference to chronic kidney
disease (CKD).
THE NEW FRONTIER OF GENETICS–EPIGENETICS
Epigenetics refers to a heritable change in the pattern of gene
expression that is mediated by mechanisms other than
alterations in the primary nucleotide (nt) sequence of genes
(Table 1).7 Epigenetic changes regulate gene expression,
silence the activity of transposable elements, and determine
gene dosage in the case of chromosome X inactivation
and genomic imprinting.7 Epigenetic mechanisms, such as
DNA methylation, histone acetylation/deacetylation, histone
methylation, and RNA interference (RNAi) are dynamic
processes and regulate gene expression patterns in normal
and diseased state (Figure 1). However, the inclusion of the
requirement for heritable transmission of patterns of gene
expression through cell division suggests that these changes
are only partially dynamic. A brief overview of these
important epigenetic modifications is given below.
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DNA METHYLATION
Many mammalian gene promoters are rich in CpG
dinucleotide clusters known as CpG islands.8 Covalent
addition of a methyl group to the 5-carbon position of the
nt cytosine is common throughout the genome, but when
added to CpG dinucleotides in promoter region, CpG islands
generally leads to loss of the associated gene expression. The
mechanism of gene silencing by DNA methylation may be
related to stearic hindrance of the transcriptional machinery,
recruitment of repressors, or alteration in chromatin
configuration9 (Figure 2). Most recent studies have focused
on this latter mechanism of gene repression. Several studies
have shown that DNA hypermethylation has an important
role in inactivation of genes such as E-cadherin, p16, MDR1,
and pi-class glutathione S-transferase.10–13 On the other
hand, DNA hypomethylation correlated with activation of
several oncogenes, although direct mechanisms for altered
expression have not been demonstrated. Rather, the associa-
tion of hypomethylation leading to genomic instability due to
generation of genomic mobile elements14 or chromosomal
break sites is supported by mechanistic evidence. Recent
studies suggest that the induction and maintenance of DNA
methylation are catalyzed by DNA methyltransferase-1 and
DNA methyltransferase-3b and are responsible for maintain-
ing abnormal promoter methylation in diseased cells.15
Furthermore, DNA methyltransferases interact directly with
histone deacetylases to recruit them to gene promoters.
CHROMATIN REMODELING (HISTONE MODIFICATION)
Regulation of higher order chromatin structure is directly
coupled with the expression of the genetic information and is
recognized as an important factor in the functional integrity,
as well as origin and evolution of genes, genome, chromo-
somes, and organism as a whole. Chromosomes are
composed of euchromatin and heterochromatin domains.
The latter generally is inaccessible to DNA-binding factors
and is transcriptionally silent. As depicted in Figure 2, gene
expression is modulated by the accessibility of chromatin
through the wrapping of the DNA around octamural
Table 1 | Definitions and description of terms
Terms Definitions
CpG islands The genomic regions that contain a high
frequency of CpG sites (300–3000 bp) mostly in
promoters of mammalian genes.
DNA methylation Addition of methyl groups to DNA, to the
5-carbon of cytosine with specific effect of
reducing gene expression.
DNA
hypermethylation
An increased level of DNA methylation acts as an
alternative to mutations to disrupt the gene
function and can predispose to genetic alterations
through inactivating genes.
DNA
hypomethylation
A decreased level of DNA methylation, which acts
as an alternative to mutations to disrupt the gene
function and can predispose to genetic alterations
through inactivating genes involved in DNA
repair.
Genomic imprinting Genomic imprinting is a distinct subset of
epigenetic regulation in which the activity of a
gene is reversibly modified depending on the
sex of the parent that transmits it.
Histone Histones are the primary protein components of
chromatin. H2A, H2B, H3, and H4 form the core
histones, which assemble to form the
nucleosome. Each nucleosome winds around
146 base pairs of DNA. The linker histone H1
locks the DNA into place forming higher-order
nucleosome structures.
Histone modification Histones are subject to post-translational
modifications at their N-terminal tails by
enzymatic processes, such as: methylation,
citrullination, acetylation, phosphorylation,
sumoylation, ubiquitination, and
ADP-ribosylation. Modification of these proteins
control chromatin states, which can be open
(transcriptionally active) or closed (inactive).
microRNA These may originate as single-stranded RNA
molecules, which form hairpin duplexes cleaved
into small dimers of 21–23 nucleotides in length,
which regulate gene expression by cleaving target
transcripts, or arresting translation.
ncRNA A ncRNA is a functional RNA molecule that is not
translated into a protein. NcRNA genes include
highly abundant and functionally important RNAs,
such as transfer RNA (tRNA) and ribosomal RNA
(rRNA), as well as RNAs such as microRNAs.
Transposable
elements
A small mobile DNA element, often of retroviral
origin, that moves within the genome, usually by
copying itself to a second site, but sometimes by
splicing itself out of its original site and inserting
in a new location.
Abbreviation: ncRNA, noncoding RNA.
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Figure 1 |Methylation of the cysteine. Epigenetic gene silencing
refers to nonmutational gene inactivation that can be faithfully
propagated from precursor cells to clones of daughter cells.
Methylation of the 5-carbon position of cytosine residues (CpG) in
DNA has long been recognized as a fundamental epigenetic
silencing mechanism. CpG methylation has recently been linked
to an even more general mechanism of epigenetic silencing and
histone modifications. Cells can inhibit the expression of
individual genes by interfering with the mRNA being transcribed.
Interaction between DNA methylation, histone modifications, and
RNA interference results in epigenetic silencing of gene. Micro
RNA (miRNA) and noncoding RNA (ncRNA) have an important
role in regulating gene expression.
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globular histone proteins to form ‘nucleosomes’. Genes
are activated if nucleosomes on chromatin are opened or
otherwise inactivated if closed.16 The accessibility of chro-
matin is reversibly regulated by the epigenetic status of DNA
methylation and histone modifications. Transcriptionally
active regions of DNA, are highly unmethylated, rich in
acetylated histones, and accessible to transcription factors,
whereas the inactive regions are comprised of methylated
DNA, deacetylated histones with compacted nucleosomes,
and unfavorable configuration to transcriptional machin-
ery.17 This inactivation of DNA is linked to histone
deacetylation through binding of methyl-CpG-binding pro-
teins to methylated promoter regions. Methylation of lysine
9 on the N-terminus of histone protein H-3 is also a
characteristic of inactive DNA, whereas methylation of lysine
4 on H-3 is a feature of activated DNA, and constitute
some of the more well-characterized components of the
increasingly complicated ‘histone code’ that regulates gene
Chromosome Chromatin Nucleosome DNA methylation
Histone modifications
Acetylation
Methylation
Phosphorylation
NH2
N
N
C
C
C
O
H
H
CH
DNMT
AcK
Me
Me
P
NH2
N
N
C
C
C
O
H
Me
CH
MeK27 MeK9 MeK9MeK27 MeK27 MeK9 MeK9MeK27 MeK9MeK27
MeK4 AcK MeK27 MeK9 MeK9MeK27
Gene ‘switched on’
• Active (open)
• Unmethylated cytosine
  (open circles)
• Acetylated histones
  (green circles)
Normal
Gene ‘switched off’
• Condensed chromatin
• Methylated cytosines
  (closed circles)
• Deacetylated histones
  (red circles)
Diseased
RNA HATs
HDemethylases
HDACs
HMTases
MeK4 AcK
Figure 2 |Mechanism of epigenetic modifications. (a) Epigenetic modifications of chromatin structure. Nucleosomes are formed and
organized into chromatin as result of DNA strands wrapped around histone octamers. Modifications of histone occur at multiple sites
because of methylation, acetylation, and phosphorylation reactions. DNA methylation occurs at 5-carbon position of cytosine residues (CpG
sites) in a reaction catalyzed by DNA methyltransferases. Together, these modifications provide a unique epigenetic signature that regulates
chromatin organization and gene expression. (b) Epigenetic changes associated with disease states. In normal healthy tissues, promoter
regions of actively transcribed genes are without DNA methylation at CpG dinucleotides (open circles) within CpG islands, and histones are
modified with predominantly active marks (lysine 4 methylation, MeK4, and acetylation of lysine 9). The transcriptional start site is open and
free of nucleosomes. This state is maintained by enzymes that modify the histone tails (histone acetyltransferases (HATs) and histone
demethylases (HDemethylases)). Intra- and intergenic regions have predominately methylated CpGs and inactive histone modifications
(lysine 9 and lysine 27 methylation). In diseased states, methylation of CpG sites within CpG islands is associated with repressive chromatin
marks, with these changes resulting from the presence of histone deacetylases (HDACs) and histone methyltranserferases (HMTases).
Repressive chromatin marks lead to compaction of chromatin and nucleosome occupancy at the transcriptional start site, preventing gene
transcription.
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expression.18 The heterochromatic state is epigenetically
inherited and changes in heterochromatin state allow a
transition from DNA sequence-specific genetic control to
an adaptive sequence-independent dynamic epigenetic
control.19
RNA INTERFERENCE
Fire and Mello, among others, discovered that double-
stranded RNA could specifically silence the function of an
endogenous gene.20 MicroRNAs (miRNAs) are a class of
endogenous, small, noncoding 21- or 22-nt RNAs that have
been implicated in the regulation of multiple biological
processes. The first evidence for gene disruption called RNAi
by double-stranded RNA came from elegant experiments
conducted on Caenorhabditis elegans.20 Thus, RNAi and
related RNA silencing pathways have emerged as new
mechanisms for the regulation of the structure and activity
of genes. Both RNAi and miRNA decrease the level of the
target protein within cells; RNAi decreases the steady-state
mRNA levels, whereas miRNA usually impairs the efficiency
with which mRNA is translated into protein.21
These short double-stranded RNAs can also cause a
transcriptional silencing through methylation of homologous
DNA promoter sequences22 and/or formation of hetero-
chromatin.23 Knockout of the miRNA-producing enzyme
Dicer1 in mice is lethal, with Dicer1-null embryos depleted of
stem cells.24 It appears that the patterns of miRNA expression
are tightly regulated and have crucial roles in cell prolifera-
tion, apoptosis, and differentiation. Indeed, the links between
RNA-silencing factors and inherited or acquired genetic
disorders are increasingly being identified.25 For instance,
miRNAs have been shown to regulate adipocyte differentia-
tion,26 insulin secretion,27 and immune function.28
EMERGING TRENDS IN ANALYZING EPIGENETIC
MODIFICATIONS
The capacity to analyze DNA methylation patterns of the
entire genome will enable us to understand how DNA
methylation influences chromatin function, and the role in
normal development, as well as disease state. The methods
available to study the epigenetic changes have increased
exponentially over the past decade. Detailed description of
the methods is beyond the scope of this review and the reader
is referred to these reviews.29–31 An overview of the
methodology is given below.
The methods for detection of DNA methylation are
based on one of the three primary ways to distinguish
methylated cytosine from unmethylated cytosines: bisulfite
conversion, digestion with methylation-sensitive restriction
enzymes, and affinity purification of methylated DNA.
Sodium bisulfite treatment selectively deaminates cytosine,
but not 5-methyl cytosine to uracil. The resulting sequence
differences between a methylated and unmethylated cytosine
can be determined by direct sequencing (specific restriction
digestion,32 nt extension assays,33 primer-specific PCR,34 or
pyrosequencing).35 Affinity purification takes advantage of
the methyl-binding domain, which binds to methylated CpG
sites.36 This technique measures the density of methylation in
a given region, and can be used for genome wide analyses
when combined with genomic DNA arrays or with high-
throughput sequencing. This analysis, however, does
not provide the base pair resolution of bisulfite-based
approaches.
Commercial oligonucleotide arrays are currently available
for large-scale analysis of DNA methylation.37 The most
recent and exciting technique is the deep sequencing, which
provides a quantitative measure of methylation abundance
rather than relative measure of methylation abundance
delivered by the array-based methods.38,39
Recruitment of methyl-CpG-binding proteins (MeCP2)
by DNA methylation silences gene expression partly by
affecting the histone deacetylase activity and chromatin
remodeling.40 Immunoprecipitation (chromatin immuno-
precipitation) using antibodies specific for a histone modi-
fications and microarray analysis is performed to analyze the
histone modifications such as H3 and H4 acetylation, H3 Lys
4 dimethylation (H3-di-meK4), and trimethylation (H3-
tri-meK4).41,42
EPIGENETICS, DEVELOPMENTAL BIOLOGY AND
STEM CELL RESEARCH
During development, cells undergo major epigenetic repro-
gramming.43 As the DNA sequence of the human genome is
the same in all cells in a given organism, the epigenome must
vary from tissue to tissue, controlling the differential
expression of genes and conferring specific identity to each
cell type. De Bustos et al.44 generated chromosome-wide
methylation profiles of different tissues and noted very
different methylation profiles from different organs, con-
firming the existence of tissue-specific epigenetic modifica-
tion patterns across chromosome 1. Other investigators have
shown that methylation profiles of the same tissue correlate
better across individuals than do profiles of different tissues
from the same individual.45,46
Genomic parental imprinting is a process involving
acquisition of DNA hypermethylation in one allele of a gene
early on in the male and female germ line that leads to
monoallelic expression.47 Phenotypic plasticity determined
by genetics is altered by epigenetic changes. Fraga et al.48
demonstrated that although monozygotic twins were indis-
tinguishable during the early years of life, approximately one-
third of monozygotic twins display epigenetic differences in
DNA methylation and patterns of histone modification with
aging. This provides additional evidence that different
phenotypes can originate from the same genotype through
epigenetic drift, which must result from external factors,
including exposures.
The explosion of stem cell research has unveiled another
area of importance for epigenetics. As for normal differentia-
tion, the reprogramming of somatic cells can not alter the
primary DNA sequence, and thus must involve epigenetic
preprogramming as cells progress through several stages
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before the full pluripotent state is attained. This involves
distinct epigenetic changes, including the reactivation of
critical endogenous pluripotency related genes, establishment
of appropriate bivalent chromatin domains, and DNA
hypomethylation of genomic heterochromatic regions.49
The process of artificial somatic cell reprogramming by
epigenetic approaches is highly relevant to research directed
toward kidney regeneration.50,51 Therefore, an understanding
of epigenetics is vital to the advancement of stem cell
therapies.
GENES, ENVIRONMENTAL INTERACTIONS, AND EPIGENETICS
Environmental signals could modify the intracellular path-
ways that directly remodel the ‘epigenome’52 (Figure 3).
Imbalances in dietary nutrients could lead to hypomethyla-
tion and genetic instability.53 Methyl groups are acquired
through the diet and donated to DNA through the folate and
methionine pathways. Indeed, global 5-methyl cytosine
content is influenced by nutritional availability of folate.54
Infections, especially viruses, are known to trigger DNA
methylation.55 Loss of methylation and the resultant weak-
ening of transcriptional repression can lead to re-expression
of normally silenced genes, such as imprinted genes, and
potentially harmful expression of inserted viral genes and
repeat elements.56 Epidemiological studies have suggested a
link between tobacco exposure and aberrant DNA methyla-
tion.57 Sensitivity to environmental exposure may vary
depending on the underlying genetic variants that predispose
to epigenetic changes,58 providing an explanation for the
interactions between genotype and environment. For in-
stance, polymorphism in the methylenetetrahydrofolate
reductase gene is associated with altered DNA methylation
in response to diet, alcohol consumption, and disease
manifestation.59,60 Thus, DNA methylation patterns fluctuate
in response to changes in diet, inherited genetic polymorph-
isms, and exposure to environmental factors.
EPIGENETIC BASIS FOR HUMAN DISEASES
Epigenetics has a very important role in pathogenesis of a
number of human diseases.5,61 Epigenetic-related diseases
have the following characteristics: (a) a heritability that could
not be fully explained by strict genetic inheritance patterns;
(b) evidence of the influence of imprinting, that is, maternal
diet or other in utero exposure influences the development
of the disease in offspring well after adulthood; and (c) an
increase in prevalence with aging. An epigenetic model of
complex disease has been proposed,19,61 which suggests
that with progressive accumulation of epimutations over the
life of the individual, a critical threshold is reached, beyond
which the genome, cell, or tissue can no longer be able
to function normally, leading to the disease phenotype.
Recently, Feinberg and coworkers proposed a common
disease genetic-epigenetic model, which provides an epide-
miological framework that endeavors to integrate epigenetic
changes with genetic variation in the context of age-related
susceptibility to disease.62,63
IS EPIGENETICS THE EPICENTER OF CKD PHENOTYPE?
The field of epigenetics of CKD is in its infancy. However, the
plethora of metabolic alterations and coexisting inflamma-
tion in CKD could incite diverse epigenetic changes.
Emerging science indicates that epimutations may be
involved in the initiation and progression of renal disease.
RNAi and renal homeostasis
There is accumulating evidence that RNAi is highly
important for the development and progression of renal
disease.64 The miRNAs are critical in the maintenance of
glomerular homeostasis and RNAi may be important in the
progression of renal disease.65 When Dicer, an enzyme that
generates miRNA was inactivated in mouse podocytes, the
mice developed proteinuria and died subsequently from renal
failure.66 The glomeruli demonstrated foot process efface-
ment, podocyte apoptosis, mesangial expansion, and
glomerulosclerosis.65 Similarly, interruption of miRNA bio-
genesis in mouse podocytes resulted in proteinuria, podocyte
dedifferentiation, and crescent formation, leading to end-
stage kidney diseases.67,68
Is renal fibrosis an epigenetic phenomenon?
Emerging data suggest that a strikingly large percentage of
patients with acute kidney injury do not completely recover
renal function, and that this population contribute to the
growing epidemiology of CKD and end-stage renal disease
(ESRD).69 Yang et al.70 observed that in severe acute kidney
injury there is a marked increase in the number of proximal
tubule epithelial cells arresting in the G2/M phase of the cell
miRNA
ncRNA
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Mutations
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modificationPhenotype
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Drugs
Figure 3 |Genetic–epigenetic phenotype. Each cell has its own
epigenetic signature, which reflects genotype and environmental
influence, and is ultimately reflected in the phenotype of the cell
and organism. Thus, most genetic findings must be considered in
an epigenetic and environmental context. The contribution from
traditional genetics cannot be unequivocally realized until the
complementary epigenetics and environmental changes are
considered.
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cycle. These cells activate c-jun NH(2)-terminal kinase (JNK)
signaling, which acts to upregulate the production of
profibrotic cytokines such as transforming growth factor-b1
and connective tissue growth factor. Thus, cell-cycle arrest
converts normal epithelial cells to cells that promote the
activation of fibroblasts. Epithelial–mesenchymal transition is
a process by which differentiated epithelial cells undergo
phenotypic transition to the matrix producing fibroblasts
and myofibroblasts.71,72 Interestingly, Bechtel et al.73 demon-
strated that hypermethylation of RAS protein activator like-1
(RASAL1) is associated with the perpetuation of fibroblast
activation and fibrogenesis in the kidney. RASALI encodes
an inhibitor of the RAS oncoprotein, which is involved
in cellular signal transduction regulating cell growth,
differentiation, and survival. RASAL1 hypermethylation is
mediated by the methyltransferase Dnmt1 in renal fibrogen-
esis, and kidney fibrosis is ameliorated in Dnmt1(±)
heterozygous mice. Thus, preliminary evidence suggests that
epigenetic modifications orchestrates the cellular reprogram-
ming leading to glomerular and interstitial fibrosis through
transcriptional regulation.74
Homocysteinemia and epigenetics in CKD
Hyperhomocysteinemia with elevated S-adenosylhomocys-
teine levels has been reported in CKD and ESRD patients.75
Analysis of a subpopulation of the Framingham Heart Study
has identified the role of methenyltetrahydrofolate synthase
gene in the progression of CKD.76 The homocysteine
precursor S-adenosylhomocysteine, a powerful competitive
inhibitor of S-andenosyl methionine-dependent methyltrans-
ferases is increased in various models of hyperhomocystei-
nemia including uremia,77 providing a mechanism for altered
DNA methylation. Indeed, increased S-adenosylhomocys-
teine levels leading to DNA hypomethylation has also been
reported in CKD patients with vascular disease.78 Thus, it is
reasonable to suggest that epigenetic modifications may be an
important risk factor for progression of renal disease and
cardiovascular disease (CVD) in patients with CKD.
DNA methylation and CVD in ESRD
Progressive decline in renal function is associated with
inflammation, augmented oxidative stress, accumulation of
diverse toxins, and deranged metabolism, all of which could
result in altered epigenetic modifications79 (Figure 4). While
Nanayakkara et al.80 did not find any association between
DNA methylation (as measured by 5-methylcytosine/total
cytosine ratio in peripheral blood leukocyte) and renal
function parameters or markers of atherosclerosis in early
stages of CKD, Stenvinkel et al.78 reported global DNA
hypermethylation (as defined by HpaII/Msp1 ratio using the
luminometric assay) in patients with and without CKD. The
Cox regression model demonstrated that DNA hypermethy-
lation associated with both all-cause and cardiovascular
mortality. It is possible that the observed hypermethylation in
CKD patients is due to interleukin-6-induced upregulation of
the DNA methyltransferase gene expression.81
EPIGENETIC REGULATION OF IMMUNE RESPONSE
Data from our laboratory have reported that patients with
CKD have abnormal immune response and activation
of proinflammatory cytokines.82 The activation of immune
response is a highly coordinated multistep process that
involves epigenetic changes.83,84 Dynamic adaptations in
both methylation and acetylation are essential to mount an
immune response against a specific antigen.85 Lymphoid
progenitor cells are committed to become either T or B cells
and then to CD4 or CD8 and to T-helper (Th)1 or Th2
lineages through expression of CD4 and CD8 and the T-cell
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Figure 4 |Chronic kidney disease (CKD) phenotype and epigenetics. Progressive decline in renal function and its complications could be
the result of genetic predisposition interacting with the epigenetic changes. Uremia-induced adverse environmental factors may alter the
epigenetic marks on the DNA or chromatin. A number of biochemical pathways and signaling cascades could be disturbed by aberrant
methylation, which could contribute to the spectrum of abnormalities seen in patients with CKD.
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receptor–CD3 complex. The orderly expression of transcrip-
tion factors and other signaling molecules determines
sequential gene expression that is regulated by epigenetic
control factors.86,87 Impaired gene silencing may lead to a
disorganized immune activation and excessive activation of
cytokines.88 For instance, inactivation of suppressors of
cytokine signaling (SOCS) gene by hypermethylation can
induce aberrant inflammatory response through suppressors
of cytokine signaling.89 It has also been suggested that
interleukin-6 might modulate epigenetic changes in cells via
regulation of DNA methyltransferase gene expression.81
Thus, chronic inflammation may be one of the mechanisms
whereby reduced renal function affects DNA methylation
in CKD.
ROLE OF EPIGENETICS IN THE METABOLIC MEMORY IN
DIABETES
Diabetic nephropathy is now the most common reported
cause of ESRD in developed nations.90 Polymorphisms in
genes involved in insulin secretion and response have been
shown to be associated with diabetes. Interestingly, there is
evidence that prenatal glucose and insulin levels influence the
risk of developing type 2 diabetes mellitus later in life,
independent of genetic predisposition.91 Several genes
involved in glucose metabolism, including facilitative glucose
transporter-492 and uncoupling protein-2,93 exhibit differ-
ential DNA methylation in their promoters. Indeed, DNA
methylation is likely to be involved in the propagation of
insulin resistance in insulin-target tissues.94–97
The Diabetes Control and Complications Trial and its
follow-up study, the Epidemiology of Diabetes Intervention,
reported a sustained effect of previous glucose control on
subsequent clinical outcome, despite change in glycemic
status.98 This phenomenon of ‘metabolic memory’ was first
described in 1987 by Engerman and Kern,99 who reported
that the incidence of retinopathy in dogs that were switched
to good glycemic control after 2.5 years of poor glucose
control was similar to those animals that were exposed to
poor glycemic control over the 5 years of the study. Although
accumulation of advanced glycation end products has been
touted as a potential mechanism for metabolic memory,
epigenetic modifications is proposed as an alternative
explanation.100,101 El-Osta et al.100 showed that transient
exposure to hyperglycemia induced epigenetic changes in the
promoter of the nuclear factor kB subunit p65 in aortic
endothelial cells both in vitro and in nondiabetic mice,
leading to increased p65 gene expression. This was associated
with mobilization of set7/9 protein, a histone methyltrans-
ferance that methylates the fourth lysine residue of the H3
histone tail.
EPIGENETIC MODIFICATIONS AND ATHEROSCLEROSIS
CVD is the most important cause of death in patients with
CKD.102 Newman proposed that aberrant DNA methylation
may be involved in atherogenesis.103 Cells with abnormal
DNA methylation assume a gene expression pattern that
favors proliferation and dedifferentiation, leading to a
transformed cellular phenotype. Interestingly, lipoproteins
induce DNA hypermethylation in cultured endothelial
cells.104 Early atherogenesis is associated with rearrangements
of DNA methylation patterns involving both hypo- and
hypermethylation. However, in advanced phases of the
disease, cellular proliferation results in a predominant DNA
hypomethylation.105 Hyperhomocysteinemia is associated
with an increased risk of CVD.106 Indeed, circulating homo-
cysteine levels were significantly correlated with the extent
of DNA methyl group loss in advanced atherosclerosis.107
A marked reduction in the content of methylated CpG
dinucleotides in extracellular superoxide dismutase gene is
observed in atherosclerotic aortas.108 Estrogen receptor-a
displays higher levels of DNA methylation in atheromas.109
Inhibition of monocarboxylate transport expression by DNA
methylation has also been implicated in the development
of atherosclerotic lesions.110 Epigenetic alterations in the
chromatin structure have been shown to regulate myocardial
gene expression. Genes known to be essential in maintaining
homeostatic cardiac physiology are modulated by DNA
methylation.111
Mitochondrial transcription factor A (TFAM), which is
essential for mtDNA transcription and replication. Studies in
transgenic mice model show that overexpression of TFAM
gene inhibit left ventricular remodeling after myocardial
infarction.112 The promoter of human TFAM contains CpG
dinucleotides and is regulated by DNA methylation.113
Investigators have shown that transgenic mice with deleted
mt-TFAM allele developed dilated cardiomypathy.101,102
Thus, epigenetic alteration could be a key factor behind
accelerated atherosclerosis and abnormal cardiac remodeling
in patients with CKD.
THE PROMISE OF EPIGENETICS—EMERGING THERAPEUTICS
OPTIONS
As the gene itself is not mutated by methylation nor is the
chromatin irreversibly changed, epigenetic gene regulation is
theoretically amenable to intervention. The epigenome
normally displays more developmental and temporal varia-
bility, it is more susceptible to environmental influences.
Thus, the importance of avoiding adverse environmental
exposure and dietary modification in the management
of epigenetic diseases could not be overemphasized. In an
interventional study, Ingrosso et al.114 examined the effect of
folate administration on DNA methylation in ESRD patients
with hyperhomocysteinaemia. Preliminary findings from
this study support that hyperhomocysteinaemia-induced
DNA hypomethylation could be reversed by administration
of folate.103
A number of epigenetic drugs are in various stages of
development; however, they lack target specificity.115 These
nucleoside analogs and nonnucleoside analogs are known as
DNA methylation inhibitors.115 Myelodysplastic syndrome
and secondary acute myeloid leukemia that are resistant to
standard chemotherapy have been treated with DNA
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methyltransferase inhibitors such as 5-azacytidine and
decitabine with good prognosis.116 The histone deacytylase
inhibitors comprise a large, diverse class of drugs that include
short-chain fatty acids, hydroxamic acids, benzamides, and
cyclic tetrapeptides.
All trans-retinoic acid and 13-cis-retinoic acid induce
hyperacetylation. Use of these medications is also being
explored in the management of pauci-immune vasculitis.
Theoretically, RNAi (small interfering RNA) might be used to
treat any disease that is linked to overexpression of a specific
gene. Thus, this technique might be relevant to genes
involved in inflammation, proliferation, and fibrosis. Indeed,
nucleic acid-based interventions are being explored for
atherosclerosis and progressive renal diseases.117
PERSPECTIVE ON EPIGENETIC RESEARCH IN NEPHROLOGY
Despite the explosion in the science of epigenetics and
emerging evidence that this phenomenon is important in the
pathogenesis of diverse complex disease traits, it remains the
domain of the oncologists. Although there is cautious foray
in to the arena of epigenetics by other fields of medicine,
such research is predominantly bench research with few
pioneering publications exploring clinical significance of
epigenetics in renal disease.
Efforts are underway to perform simultaneously gene
expression studies performed together with epigenomics
analysis in order to identify new diagnostic and prognostic
markers for progressive renal disease. Lack of large scale
epigenetic studies may be because of the uncertainty
regarding the utility of traditional DNA source from peri-
pheral blood mononuclear cells for the study of epigenetic
epidemiology.
Researchers have detected the presence of methylated
DNA in serum/plasma from patients with various types of
malignancies.118,119 It is presumed that circulating DNA is
derived from DNA released from tumor cells from the site of
disease activity.120 It is reasonable to speculate that in
systemic diseases, such as diabetes, CKD, and atherosclerosis,
DNA derived from peripheral blood mononuclear cell could
be used as a viable surrogate for localized organ-specific
diseases.78,80,96,121 Study of longitudinal changes in epigenetic
modifications could be highly relevant, especially when
demonstrated to precede the change in cellular or clinical
phenotype.73,109 Demonstrating such change could indicate
causality and potentially lead to targeted interventions.
Genetics of common diseases can be explained by
interplay of genetic and epigenetic variation.122 For instance,
genetic variations could introduce or remove CpG sites,
which are susceptible to methylation. Loss of imprinting of
insulin-like growth factor 2 (IGF2) gene is noted in 10% of
individuals with no clinical manifestation of Beckwith–
Wiedeman syndrome, an imprinted growth disorder. Specific
haplotypes within the IGF2 gene have been associated with
loss of methylation at the locus in Beckwith–Wiedeman
syndrome patients, suggesting that epigenetic and genetic
variation may act synergistically to influence a phenotype.123
Thus, future studies should consider the interaction between
genotype and epigenotype in determining phenotype and
therapeutic consequences.
CONCLUSION
Epigenetics has revolutionized the field of genetics leading to
re-evaluation of the traditional concepts of heritability and
genetics. Chromosomal instability as a result of DNA
hypomethylation and silencing of genes due to hypermethy-
lation has been reported in a variety of disorders beyond
cancer. Inflammation and metabolic stress encountered in
CKD could promote epigenetic changes, leading to altered
gene expression and abnormal cellular function. Advances in
understanding of epigenetic modifications in the progression
of CKDs could be of great significance in predicting the pace
of disease progression, developing targeted therapeutic
strategies in preventing the progression of CKD, and
providing an effective treatment of uremia-related complica-
tions.
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